Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Lenvima“
Suchtreffer
Begriffe & Kennungen
Lenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), QT/QTc interval prolongation was reported in 6.9% of lenvatini
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), arterial thromboembolic events were reported in 2.3% of patien
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), cardiac dysfunction (including congestive cardiac failure, car
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), diarrhoea was reported in 38.7% of patients treated with lenva
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), events of gastrointestinal perforation or fistula were reporte
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), haemorrhage was reported in 24.6% of patients and 5.0% were Gr
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), hypertension (including hypertension, increased blood pressure
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), hypocalcaemia was reported in 1.1% of patients, with grade 3 r
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), proteinuria was reported in 26.3% of lenvatinib- treated patie
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), the most commonly reported hepatotoxicity adverse reactions we
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), there was 1 event of PRES (Grade 2) in the lenvatinib-treated
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), 18.2% of lenvatinib plus pembrolizumab-treated patients developed
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), QT interval prolongation was reported in 3.9% of lenvatinib plus p
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), arterial thromboembolisms were reported in 3.7% of lenvatinib plus
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), cardiac dysfunction was reported in 1.0% of lenvatinib plus pembro
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), diarrhoea was reported in 54.2% of lenvatinib plus pembrolizumab-t
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), events of fistula formation were reported in 2.5% of lenvatinib pl
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), haemorrhage was reported in 24.4% of lenvatinib plus pembrolizumab
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hepatotoxicity was reported in 33.7% of lenvatinib plus pembrolizu
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hypertension was reported in 65% of patients in the lenvatinib plu
Eintrag öffnen